Colin Weekes教授在波士顿哈佛医学院的血液学/肿瘤学系任职，同时是麻省总医院Tucker Gosnell胃肠癌中心胰腺癌医学肿瘤研究主任，专注于胰腺癌患者的临床和转化研究，他所带领的研究小组的目标是将生物学原理纳入胰腺癌患者的治疗中。目前他正在与基础科学家合作，旨在将靶向治疗和疾病反应的生物标志物整合到临床试验开发中。

除了从事胰腺癌的工作外，Weekes博士还致力于胃肠道恶性肿瘤的早期药物开发。他的临床兴趣包括胰腺癌，结肠癌和直肠癌，以及肝癌，包括胆管癌和肝细胞癌。他可以治疗多种类型的癌症患者，包括结肠直肠癌，食道癌，胆囊癌，胃肠道癌，肝癌和胃癌。

履历

Colin Weekes教授毕业于美国内布拉斯加大学医学中心(UNMC)，并在UNMC获得了两个硕士学位(1998年在UNMC获得博士学位，2000年获得医学学位)。作为UNMC的优秀学员，2018年Colin Weekes教授被邀请出席12月12日的UNMC研究生荣誉大会，并在大会发表了演讲。

正在UNMC研究生荣誉大会演讲的Colin Weekes教授

图源：unmc.edu

医学院毕业后，Colin Weekes教授成为了阿拉巴马大学医学院内科住院医师，并获得获得约翰·霍普金斯医院(Johns Hopkins Hospital)医学肿瘤学研究金，该研究金专注于开发胰腺癌新疗法的转化研究。

之后，Colin Weekes教授在科罗拉多丹佛大学安舒兹医学校园的肿瘤内科任教。

2017年，Colin Weekes教授加入麻省总医院，成为了麻省总医院Tucker Gosnell胃肠癌中心胰腺癌医学肿瘤研究主任。

成就

约翰·霍普金斯医院(Johns Hopkins Hospital)医学肿瘤学研究金

美国内科医学委员会认证

医学肿瘤学认证

美国临床肿瘤学会(ASCO)活跃成员

美国癌症研究协会(AACR)活跃成员

专业领域

胰腺癌、结肠和直肠癌、胆管癌、肝细胞癌、临床试验，开发新药组合、新药的临床试验

部分著作

Michelakos T, Cai L, Villani V, Sabbatino F, Kontos F, Fernández-Del Castillo C, Yamada T, Neyaz A, Taylor MS, Deshpande V, Kurokawa T, Ting DT, Qadan M, Weekes CD, Allen JN, Clark JW, Hong TS, Ryan DP, Wo JY, Warshaw AL, Lillemoe KD, Ferrone S, Ferrone CR. Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. Journal of the National Cancer Institute 2020.

Rodrigues C, Hank T, Qadan M, Ciprani D, Mino-Kenudson M, Weekes CD, Ryan DP, Clark JW, Allen JN, Hong TS, Wo JY, Ferrone CR, Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 2020.

Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio B, Goyal L, Nipp RD, Roeland E, Weekes CD, Wo JY, Zhu AX, Dias-Santagata D, Iafrate AJ, Lennerz JK, Hong TS, Siravegna G, Horick N, Clark JW, Corcoran RB. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res 2020.

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019.

Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol 2018.

Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist 2018.

Weekes CD, Rosen LS, Capasso A, Wong KM, Ye W, Anderson M, McCall B, Fredrickson J, Wakshull E, Eppler S, Shon-Nguyen Q, Desai R, Huseni M, Hegde PS, Pourmohamad T, Rhee I, Bessudo A. Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2018.

Weekes CD, Clark JW, Zhu AX. Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target? Lancet Oncol. 2018; 19:591-592.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15:1028-1061.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer 2017; 116:575-583.

Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, D'Alessandro A, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, Eisenmesser EZ. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. 2018; 8:6742-6762.